The doctrine that we are all equal under God applies in reality to the very Blood of humanity that runs through our veins. This was the shocking truth that changed an age old way of intellectual & class division. After millennia Science did that not faith. The fluid of life is an interchangeable commodity that drives the body and mind. A genetic brain unique to a person's cells is common enough to be of practical benefit. Donors of all types, colors and creeds can have some siphoned off and provided to those that need a refill.
We accept the DNA of another to live on, with new Blood, without question and without any harm.
With 7.2 Billion humans on the planet you would think that we'd have enough of the Red stuff to go around. Think again. We don't even have enough fresh supplies to meet current demand, let alone future requirements based on the donation system. How can we expect this system to suddenly change to meet the forecasted demand when the population hits 10 Billion within a few decades and then 15 Billion a generation or two later?
Enter science, as usual, to solve the human evolutionary dilemma - Create it.
Not only is it possible to do so now, in inexhaustible volumes to satisfy all, but those cell products can and will be modified by the Scientists & Doctors of this 2nd Blood Revolution to deliver the needed solutions against the parasites, funguses, viruses, bacterias et al. that plague & kill daily in countless numbers.
Engineered weapons of the vascular system that naturally hone in and destroy invading pathogens.
The below provides a rough summary of how this is coming together from the perspective of ACTC and it's scientific colleagues.
Phase 1 - Blastomere Derived Renewable Stem Cell Line
Phase 2a - Clinical Expansion & Banking of Hemangioblast Derived Megakaryocytes
Phase 2b - Engineered Variants for Drug Delivery Requirements
Phase 3a - Differentiation of Platelets, Red Blood Cells & Line Derivatives
Phase 4a - Biocompatible Unit Preparation & Universal Distribution
Phase 4b - Locally Served Fresh Product via Bioreactor Automated Production
Cell Research Jan 2011 - "Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice" - SCRMI, Univ of Illinois Chicago, Cha Univ, Harvard / BWH & ACTC
Blood July 2014 - "Platelet bioreactor-on-a-chip" - Harvard / BWH, Univ Colorado & Colorado School of Mines, McGill, ACTC
Vector - Boston Children's Hospital Blog March 2014 - "The Platelet Whisperers"
MedCity News April 2014 - "Biochip mimics how the body produces platelets so they could be made in a lab"
NY Times May 2014 - "Young Blood May Hold Key to Reversing Aging"
UCSF July 2014 - "Key to Aging Immune System Is Discovered"
Proceedings of the National Academy of Sciences of the USA, June 2014 - Whitehead Institute & MIT - "Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes"
The Scientist Sept 2014 - "Next Generation: Blood-Cleansing Device" - (Engineered MBL Protein use example in fighting Sepsis - with cell engineering it can be done without dialysis)
Dr. Langer's Lab & Dr. Jensen's Lab of MIT
The Scientist July 2013 - "Narrow Straits - Transfecting molecules into cells is as easy as one, two, squeeze."
Proceedings of the National Academy of Sciences of the USA, Feb 2013 - "A vector-free microfluidic platform for intracellular delivery"
R&D, July 2013 - "Researchers put squeeze on cells to deliver"
Dr. Daley's Lab - "Hematopoiesis Research" - HHMI / Children's Hospital Boston / Havard & "CellNet" - Children's Hospital Boston / Havard / Boston Univ & iPS mRNA Tech
Daley / Children's Hospital Boston / Harvard Patent Families:
Biomechanical Induction of Hematopoiesis
Inhibition and Enhancement of Reprogramming by Chromatin Modifying Enzymes
Methods for Enhancing Hematopoietic Progenitor Cell Engraftment
Method to Produce Induced Pluripotent Stem (iPS) Cells from Non-Embryonic Human Cells
Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells
Advanced Cell Technology's Patent Portfolio for the Blood Program:
INEXHAUSTIBLE SOURCE OF RENEWABLE STEM CELLS:
Blastomere Non-Destructive Human Embryonic Stem Cell Technology
Blastomere Patent Family
5 Granted US Patents: 1, 2, 3, 4, 5
iPS/Reprogramming Renewable Stem Cell Derivation papers 1 & 2
iPS/Reprogramming Renewable Stem Cell Patent Family Portfolio: 1, 2 with examples A, B, C and SCNT Tech
EARLIEST YOUTHFUL BLOOD LINE POSSIBLE
HEMANGIO-COLONY FORMING CELLS - US Patent Granted & Patent Family
HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS - App Pub March 2011 & Patent Family
UNIQUE BLOOD LINE CELL PRODIGY DERIVATION:
(WO2011069127) LARGE SCALE GENERATION OF FUNCTIONAL MEGAKARYOCYTES AND PLATELETS FROM HUMAN EMBRYONIC
STEM CELLS UNDER STROMAL-FREE CONDITIONS - PCT Pub June 2011 & US App Pub Dec 2012 & Patent Family
(Note: SCRMI is a JV between ACTC & Cha Biotech of Korea - North American Rights belong to ACTC - Japan/Korea to Cha - ROW split)
(WO2014100779) METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - PCT Pub June 2014 & US App Pub Sept 2014